If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
I think this is overall positive. Reducing staffing costs, they don't have debt so this will help. They probably can get reasonable debt financing over a term of three to five years. Selling, the other alternative, I agree think this will be snapped up. No dilution
Sir Chris Evan's would never state 'hugely' encouraging, and give the large reduction in all cause mortality in Covid stated unless data are compelling. His credibility would otherwise be called to account. The drug has a very good safety profile and has already been administered to 1000+ diabetes individuals. Numbers will be tied into the commercial discussions, as will route to market.
A strong trend towards reduced mortality in patients receiving AZD1656. This was noted in both mortality on treatment and all-cause mortality, which were lower in the AZD1656 group compared to the placebo group. The strong trend to improved mortality for patients on AZD1656 was observed on top of patients receiving other medication, including dexamethasone, as part of standard of care. C
Just going through the presentations, and results were positive ('promising') for part A of the trial. They started recruiting for B at that point, an additional 6 cohorts. Why would they have initiated this and have two presentations/ posters included relatively last minute (news, Aug 2nd) unless there is additional positive data from Keytruda + DDDD's bacterium. Looking forward to news preceding the 16th. It must RNS=worthy, they've stated this.
Wrong company, sorry!
Was just looking through the presentations, and the results were positive from part A of the trial. They then started recruiting for B. Why would they have two presentations/ posters which were included relatively last minute (news, Aug 2nd) unless there is additional positive data from Keytruda + DDDD's bacterium. Looking forward to the news preceding the 16th. It must be worthy of an RNS, they've already stated this.
https://rover-labs.com/article-prnewsire
Cloud Lis, designed for the Mologic test, as part of RdX, can automatially send test results to goverment agencies to meet contact tracing reqs.
The EUA forms were submitted at the end of July/ beginning of last month, this is approx turnaround time now. UK tests only passed in the last six weeks. Cloud-based system customisation for the Mologic test is recent. Buy out of Mologic by Bill Gates ect only just preceded this, so several signs are there
We're entering a news rich period- EUA for Visitect/ Mologic test in the US, shored up by the Bill and Melinda Gates foundation and RadX, multiple signals (Mologic US lease, Columbia University RADX (US-NIH) software bespoke for home testing specifically for the Mologic test, signs are there that this will be given anyday, and incoming US revs. Then also the GOVT contract for a UK test. Numerous MPs have stated a UK test has passed PD criteria so again forthcoming, I think this is probably the Surescreen test, but the manufacturing revs will be a gamechanger and with schools back and cases rising, this is highly likely to be ramped up asap
In addition to exclusive self antibody test manufactiure, TT due on the Avcta antigen test, should be any day now. 'The Board anticipates ALLof these products will contribute meaningfully to contract manufacturing revenue growth in FY 21/22.' So still all go.Also they have made their own test semi-quantitative and this should be in the public domain shortly.
Hats off to them. The high commision has serious reach and 16000 followers. Plus they really emphasis the cutting edge tech and 99.9% 7hrs killing of the virus, I think a lot could come from this, very very good publicity
This test is targeting surface antigen. Once the individual has mounted an antigen-specific immune response by producing antibodies, CD T helper cells ect (this is usually later in the infection), the antigen is usually internalised or degraded and so shouldn't be present and so shouldn't give a positive signal. PCR tests detect specific sections of viral DNA using primer pairs, the DNA can be around for a while later (it's a stable molecule) although it will be eventually cleared in healthy individuals. This is why PCR can give these false +ve tests.
This test is targeting surface antigen. Once the individual has mounted an antigen-specific immune response by producing antibodies, CD T helper cells ect (this is usually later in the infection), the antigen is usually internalised or degraded and so shouldn't be present and so shouldn't give a positive signal. PCR tests detect specific sections of viral DNA using primer pairs, the DNA can be around for a while later (it's a stable molecule) although it will be eventually cleared in healthy individuals. This is why PCR can give these false +ve tests.
http://www.rns-pdf.londonstockexchange.com/rns/0204E_1-2020-2-25.pdf
If you look at this map and resuts from Feb 2020, the core published yesterday and the least mineralisation of all the holes drilled.